Analyzing...
Loading company...
Corona Remedies Ltd is a pharmaceutical company focused on branded formulations. It develops and markets prescription medicines across multiple therapeutic areas. The company emphasizes physician engagement and strong brand recall in chronic therapies. Its operations are supported by in-house manufacturing and quality control systems. Corona Remedies primarily serves the Indian healthcare market.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹1,403 Cr revenue.
COGS 18.6%, employees 28.7%.
“we are on track to deliver 15% the CACR 15% revenue growth and 20% PAT or EPS growth for next three to four years.”
“we are on track to deliver 15% the CACR 15% revenue growth and 20% PAT or EPS growth for next three to four years.”
“grow on 15% on revenue”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 24.8%▲ | 10.3% |
| ROCE | 29.3%▲ | 13.7% |
| Net Margin | 13.1%▲ | 7.6% |
| EBITDA Margin | 20.2%▲ | 15.4% |
| Debt To Equity | 0.19x▲ | 0.15x |
Historical valuation data not available.
Revenue segment breakdown not available.
| (₹ Cr) | TTM |
|---|---|
| Revenue | ₹1,403 Cr |
| Other Income | ₹11 Cr |
| Total Income | ₹1,414 Cr |
| COGS | ₹261 Cr |
| ₹1,155 Cr | |
| Profit Before Tax | ₹240 Cr |
| Exceptional Items | (₹19 Cr) |
| ₹55 Cr | |
| Net Profit | ₹185 Cr |
| Other Comprehensive Income | ₹0.11 Cr |
| EPS | ₹30.22 |
| Diluted Shares | ₹6 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
CORONA Remedies Limited has informed the Exchange about Copy of Newspaper Publication
CORONA Remedies Limited has informed the Exchange about Investor Presentation
CORONA Remedies Limited has informed the Exchange regarding a press release dated July 31, 2026, titled "Press Release on Unaudited financial results for Q1FY27".
CORONA Remedies Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
CORONA Remedies Limited has informed the Exchange about Schedule of meet
CORONA Remedies Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 09, 2026. Further, the company has informed the Exchange regarding voting results.
CORONA Remedies Limited has informed the Exchange regarding a press release dated Jun 30, 2026, titled "Press Release for Commencement of Commercial Production".
CORONA Remedies Limited has informed the Exchange about Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ...
CORONA Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
CORONA Remedies Limited has informed the Exchange about Copy of Newspaper Publication - Notice of 22nd Annual General Meeting, Intimation of Record date and E-votingInformation
CORONA Remedies Limited has informed the Exchange about Schedule of Analysts / Investor Conference
Dr. Kirtikumar L. Mehta has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regula...
CORONA Remedies Limited has informed the Exchange about Intimation of Non-Deal Roadshow
CORONA Remedies Limited has informed the Exchange about Intimation for Non-Deal Roadshow
CORONA Remedies Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Press Release - Receipt of EU-GMP Certificate".
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.